top of page
​Role of CD4/CD8 double positive T cells in modulating response to anti-PD-1 treatment in renal cell carcinoma
The Farcast TruTumor platform facilitates the study of rare immune sub-populations within the tumor microenvironment
and their modulation by drug treatments. The data indicate that a higher percentage of DPT cells is associated with improved responses to anti-PD1 therapy in RCC patients.
Enter your details to see the full poster now
bottom of page